ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för sepantronium bromide. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

25 träffar

Bibliografisk träff 2017-06-01

Rapamycin enhances the anti-angiogenesis and anti-proliferation ability of YM155 in oral squamous cell carcinoma.

Li KL, Wang YF, Qin JR, Wang F, Yang YT, Zheng LW, Li MH, Kong J, Zhang W, Yang HY.

Tumour Biol · journal article · DOI 10.1177/1010428317706213

Bibliografisk träff 2017-02-01

YM155 inhibits topoisomerase function.

Hong M, Ren MQ, Silva J, Paul A, Wilson WD, Schroeder C, Weinberger P, Janik J, Hao Z.

Anticancer Drugs · research-article; journal article · DOI 10.1097/cad.0000000000000441

Bibliografisk träff 2016-06-08

Mathematical Modeling of the Role of Survivin on Dedifferentiation and Radioresistance in Cancer.

Rhodes A, Hillen T.

Bull Math Biol · journal article · DOI 10.1007/s11538-016-0177-x

Bibliografisk träff 2016-05-05

Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.

de Haart SJ, Holthof L, Noort WA, Minnema MC, Emmelot ME, Aarts-Riemens T, Doshi P, Sasser K, Yuan H, de Bruijn J, Martens AC, van de Donk NW, Lokhorst HM, Groen RW, Mutis T.

Haematologica · letter; research support, non-u.s. gov't · DOI 10.3324/haematol.2015.139667

Bibliografisk träff 2016-02-09

A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma.

Papadopoulos KP, Lopez-Jimenez J, Smith SE, Steinberg J, Keating A, Sasse C, Jie F, Thyss A.

Leuk Lymphoma · clinical trial, phase ii; multicenter study; journal article · DOI 10.3109/10428194.2015.1113275

Bibliografisk träff 2015-10-27

YM155 suppresses cell proliferation and induces cell death in human adult T-cell leukemia/lymphoma cells.

Sasaki R, Ito S, Asahi M, Ishida Y.

Leuk Res · journal article · DOI 10.1016/j.leukres.2015.10.012

Bibliografisk träff 2015-08-01

A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model.

Guo K, Huang P, Xu N, Xu P, Kaku H, Zheng S, Xu A, Matsuura E, Liu C, Kumon H.

Oncotarget · research support, non-u.s. gov't; research-article; journal article · DOI 10.18632/oncotarget.4121

Bibliografisk träff 2015-07-01

YM155, a survivin suppressant, triggers PARP-dependent cell death (parthanatos) and inhibits esophageal squamous-cell carcinoma xenografts in mice.

Zhao N, Mao Y, Han G, Ju Q, Zhou L, Liu F, Xu Y, Zhao X.

Oncotarget · research support, non-u.s. gov't; research-article; journal article · DOI 10.18632/oncotarget.4315

Bibliografisk träff 2015-05-05

Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.

Yu Y, Zhao X, Zhang Y, Kang Y, Wang J, Liu Y.

Oncol Rep · research support, non-u.s. gov't; journal article · DOI 10.3892/or.2015.3947

Bibliografisk träff 2015-01-23

Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia.

Smith AM, Little EB, Zivanovic A, Hong P, Liu AK, Burow R, Stinson C, Hallahan AR, Moore AS.

Leuk Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.leukres.2015.01.005

Bibliografisk träff 2014-12-23

A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma.

Kudchadkar R, Ernst S, Chmielowski B, Redman BG, Steinberg J, Keating A, Jie F, Chen C, Gonzalez R, Weber J.

Cancer Med · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1002/cam4.363

Bibliografisk träff 2014-11-01

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.

Wagner V, Hose D, Seckinger A, Weiz L, Meißner T, Rème T, Breitkreutz I, Podar K, Ho AD, Goldschmidt H, Krämer A, Klein B, Raab MS.

Oncotarget · research support, non-u.s. gov't; research-article; journal article · DOI 10.18632/oncotarget.2529

Bibliografisk träff 2014-07-18

Formulation design and evaluation of liposomal sepantronium bromide (YM155), a small-molecule survivin suppressant, based on pharmacokinetic modeling and simulation.

Shakushiro K, Kawano H, Nakata M, Kita A, Maeda A, Watanabe S, Sako K, Oku N.

Pharm Res · journal article · DOI 10.1007/s11095-014-1458-4

Bibliografisk träff 2014-06-30

Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant.

Kawano H, Shakushiro K, Nakata M, Kita A, Maeda A, Watanabe S, Sako K, Oku N.

Eur J Pharm Biopharm · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejpb.2014.06.015

Bibliografisk träff 2014-01-21

Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma.

Dolman ME, den Hartog IJ, Molenaar JJ, Schellens JH, Beijnen JH, Sparidans RW.

J Pharm Biomed Anal · journal article · DOI 10.1016/j.jpba.2014.01.011

Bibliografisk träff 2013-11-28

Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells.

Huang YT, Cheng CC, Lin TC, Chiu TH, Lai PC.

Oncol Rep · research support, non-u.s. gov't; journal article · DOI 10.3892/or.2013.2882

Bibliografisk träff 2013-07-14

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.

Kelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, Poondru S, Van Sant C, Keating A, Steinberg SM, Figg W, Giaccone G.

Ann Oncol · clinical trial, phase ii; research support, n.i.h., intramural; research-article; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1093/annonc/mdt249

Bibliografisk träff 2013-06-05

Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway.

Premkumar DR, Jane EP, Foster KA, Pollack IF.

J Pharmacol Exp Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1124/jpet.113.204743

Bibliografisk träff 2013-01-16

YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.

Jane EP, Premkumar DR, DiDomenico JD, Hu B, Cheng SY, Pollack IF.

Mol Cancer Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-12-0901

Bibliografisk träff 2013-01-01

Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.

Kaneko N, Yamanaka K, Kita A, Tabata K, Akabane T, Mori M.

Biol Pharm Bull · journal article · DOI 10.1248/bpb.b13-00515

Bibliografisk träff 2012-12-28

Lack of differences in the pharmacokinetics of sepantronium bromide (YM155) between US and Japanese patients with advanced solid tumors or non-Hodgkin lymphoma.

Aoyama Y, Katashima M, Sawamoto T.

Biopharm Drug Dispos · comparative study; clinical trial, phase i; journal article · DOI 10.1002/bdd.1827

Bibliografisk träff 2012-08-16

Population pharmacokinetic modeling of sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma.

Aoyama Y, Kaibara A, Takada A, Nishimura T, Katashima M, Sawamoto T.

Invest New Drugs · clinical trial, phase ii; research-article; multicenter study; journal article · DOI 10.1007/s10637-012-9867-x

Bibliografisk träff 2012-07-27

Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression.

Yamauchi T, Nakamura N, Hiramoto M, Yuri M, Yokota H, Naitou M, Takeuchi M, Yamanaka K, Kita A, Nakahara T, Kinoyama I, Matsuhisa A, Kaneko N, Koutoku H, Sasamata M, Kobori M, Katou M, Tawara S, Kawabata S, Furuichi K.

Biochem Biophys Res Commun · journal article · DOI 10.1016/j.bbrc.2012.07.103

Bibliografisk träff 2012-07-18

Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment.

Aoyama Y, Nishimura T, Sawamoto T, Satoh T, Katashima M, Nakagawa K.

Cancer Chemother Pharmacol · research-article; journal article · DOI 10.1007/s00280-012-1913-z

Bibliografisk träff 2012-07-11

Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab.

Kita A, Mitsuoka K, Kaneko N, Nakata M, Yamanaka K, Jitsuoka M, Miyoshi S, Noda A, Mori M, Nakahara T, Sasamata M.

J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.112.195925